UNH Stock: Buy or Sell? Price Target & Forecast

Analyses / UNH

UNH UnitedHealth Group Inc As of Sep 15, 2026

$383.55

Profitable insurer facing margin pressure; 2026 outlook improving. Valuation elevated vs historical norms.

Setup: value_with_growth_headwinds Confidence: 65 Horizon: 6–12 months Risk: medium Category: Large Cap

🔒 Trade Plan — entry · target · stop

Entry Zone

$•••–•••

Target

$•••

Stop Loss

$•••

Risk / Reward

•.• : 1

Unlock the exact levels — free →

A free account reveals UNH's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.

The Thesis

▲ Bull Case

Diversified healthcare platform (insurance + Optum services) with $344B market cap & strong brand. 11.35% revenue growth, 1.37% dividend yield, insider buying (111 buys vs 28 sells) signals confidence. 2026 outlook cited as positive. Beta 0.54 suggests defensive profile.

▼ Bear Case

EPS declined -14.51% YoY; forward P/E 28.6x vs historical 20–22x reflects growth concerns. Net margin 2.69% squeezed. Rising acquisition/litigation costs (CEO commentary on 'big reset'). Current ratio 0.89 signals tight liquidity. Stock -17% from 52-week high ($461.62); price action suggests peak enthusiasm fading.

Valuation

FAIR TO SLIGHTLY OVERVALUED — score 62/100

Large-cap healthcare names typically trade 18–22x P/E in growth phases; UNH at 24.4x trailing and 28.6x forward commands premium despite -14.51% EPS decline. Revenue growth (11.35%) and scale justify mid-20s multiple, but forward P/E suggests market pricing in 2026 recovery; if reset underdelivers, re-rating risk is high. P/S 0.77 and EV/EBITDA 16.8x are reasonable for diversified insurer, but tight liquidity (CR 0.89) and squeezed margins (2.69% net) weigh.

Technical Levels

Support · $365.00 (Recent consolidation floor; entry zone low) · $350.00 (Stop-loss; 2024 breakout level (~52-week low bounce zone: 255.97)) · $370.00 (Intermediate support; 1-month MA proxy)

Resistance · $395.00 (1-month consolidation cap; minor resistance) · $410.00 (3-month target; psychological round number) · $461.62 (52-week high; major overhead; re-rating needed to clear)

RSI: Not provided in data; RSI unavailable

Financial Health

Score 62/100. Liquidity tightness (CR 0.89, QR 0.67) is primary concern; below 1.0 suggests working capital strain or aggressive cash deployment (likely post-acquisition or restructuring). Debt/equity unavailable, limiting full assessment. Margin compression ongoing but manageable given scale. Insider buying (111 vs 28 sells) and dividend (1.37% yield, 65.66% payout) suggest management confidence in recovery.

Catalysts

2026 Strategic Reset Execution	Next 12 months	HIGH — CEO commentary emphasizes 'big reset'; quarterly earnings will track progress on cost control, margin recovery, and clinic stabilization.
Q1 2025 Earnings / Guidance Refresh	Expected April 2025	MEDIUM — Confirm/adjust 2026 outlook; validate operating margin stabilization.
Optum Business Performance	Quarterly	MEDIUM — Growth engine for UNH; if Optum revenues/margins accelerate, stock re-rates higher.
M&A or Partnership Announcements	Ongoing	MEDIUM — TPG deal on clinics suggests capital redeployment; future deals could boost or strain balance sheet.
Regulatory/Litigation Outcomes	Ongoing	LOW–MEDIUM — Antitrust scrutiny, drug pricing, class actions; outcomes could impact margins and reputational risk.

Risk Flags

EPS contraction -14.51% YoY; forward guidance not fully transparent in data.

Forward P/E 28.6x elevated; PEG unavailable; growth multiples may compress further if 2026 reset disappoints.

Liquidity tightening: current ratio 0.89 and quick ratio 0.67 below healthy thresholds.

CEO commentary on 'big reset' suggests significant operational restructuring; execution risk high.

Florida clinic underperformance + TPG partnership suggests clinic operations remain challenged.

Payroll pressure and healthcare cost inflation may persist despite scale.

See UNH's full trade plan — free

Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.

Unlock UNH free →

More Analyses

AMD

Advanced Micro Devices Inc

Micron Technology Inc

CRM

Salesforce Inc

Goldman Sachs Group Inc

Visa Inc

Mastercard Inc

UNH FAQ

Is UNH a buy right now?

UnitedHealth Group Inc's current read is a value_with_growth_headwinds setup with 65 confidence over a 6–12 months horizon. Valuation: FAIR TO SLIGHTLY OVERVALUED. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.

Is UNH overvalued?

FAIR TO SLIGHTLY OVERVALUED (valuation score 62/100). Large-cap healthcare names typically trade 18–22x P/E in growth phases; UNH at 24.4x trailing and 28.6x forward commands premium despite -14.51% EPS decline. Revenue growth (11.35%) and scale justify mid-20s multiple, but forward P/E suggests market pricing in 2026 recovery; if reset underdelivers, re-rating risk is high. P/S 0.77 and EV/EBITDA 16.8x are reasonable for diversified insurer, but tight liquidity (CR 0.89) and squeezed margins (2.69% net) weigh.

What are the risks of buying UNH?